Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

Investigational New Drugs

Volumn 26, Issue 5, 2008, Pages 399-406

  Zamboni, William C ^a,b,c   Jung, Laura L ^c   Strychor, Sandra ^c   Joseph, Erin ^c   Zamboni, Beth A ^d   Fetterman, Sarah A ^c   Sidone, Brian J ^c   Burke, Thomas G ^e   Curran, Dennis P ^a   Eiseman, Julie L ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d CARLOW UNIVERSITY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Camptothecins; DB 67; Liposomes; Pharmacokinetics; Silatecans

Indexed keywords

10 HYDROXY 7 TERT BUTYLDIMETHYLSILYLCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 67; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; HYDROXYACID; LACTONE DERIVATIVE; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG FORMULATION; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SPLEEN;

ANIMALS; CAMPTOTHECIN; FEMALE; HALF-LIFE; HYDROXY ACIDS; LACTONES; LIPOSOMES; MICE; MICE, SCID; ORGANOSILICON COMPOUNDS; SPLEEN; TISSUE DISTRIBUTION;

EID: 50249110116     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9109-9     Document Type: Article

References (28)

1. TG Burke Z Mi 1993 Preferential binding of the carboxylate form of camptothecin by human serum albumin Anal Biochem 212 285 287
2. Z Mi TG Burke 1994 Differential interactions of camptothecin lactone and carboxylate forms with human blood components Biochemistry 33 10325 10336
3. Z Mi TG Burke 1994 Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study Biochemistry 33 12540 12545
4. IF Pollack M Erff D Bom 2001 Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo Can Res 59 4898 4905
5. DP Curran H Liu 1991 4+1 Radical annulations with isonitriles-a simple route to cyclopenta-fused quinolines J Am Chem Soc 113 2127 2132
6. DP Curran SB Ko 1994 Synthesis of optically active alpha-hydroxy lactones by sharpless asymmetric dihydroxylations of ketene acetals, enol ethers, and ene lactones J Org Chem 59 6139 6141
7. H Josien D Bom DP Curran YH Zheng T Chou 1997 7-Silylcamptothecins (Silatecans): a new family of camptothecin antitumor agents Bioorg Med Chem Lett 7 3189 3295
8. TG Burke Z Mi Y Jiang CB Munshi 1995 The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs J Pharm Sci 84 518 519
9. TG Burke Z Mi 1994 The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J Med Chem 37 40 46
10. IF Pollack M Erff D Bom 1999 Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo Cancer Res 59 4898 905
11. MS Newman GT Colbern PK Working 1999 Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor bearing mice Cancer Chemother Pharmacol 43 1 7
12. EA Forssen DM Coulter RT Proffitt 1992 Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors Cancer Res 52 3255 3261
13. EA Forssen 1997 The design and development of DaunoXome for solid tumor targeting in vivo Adv Drug Deliv Rev 24 133 150
14. WC Zamboni 2005 Liposomal, nanoparticle, conjugated formulations of anticancer agents Clin Cancer Res 11 8230 8234
15. WC Zamboni CF Stewart J Thompson 1998 Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts J Natl Cancer Inst 90 505 511
16. WC Zamboni AC Gervais MJ Egorin JH Schellens EG Zuhowski D Pluim E Joseph DR Hamburger PK Working G Colbern ME Tonda DM Potter JL Eiseman 2004 Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma Cancer Chemother Pharmacol 53 329 336
17. D'Argenio DZ, Schmuitzky A (1990) ADAPT II User's Guide: Biomedical Simulations Resource
18. Rowland M, Tozer T (1999) Clinical pharmacokinetics: concepts and applications. Lea and Febiger, Philadelphia
19. Z Mi H Malak TG Burke 1995 Reduced albumin binding promotes the stability and activity of topotecan in human blood Biochem 34 13722 13728
20. JA Smith RA Newman FH Hausheer T Madden 2003 Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development J Clin Pharmacol 43 1008 1014
21. CJ Punt MJ de Jonge S Monfardini G Daugaard W Fiedler B Baron D Lacombe P Fumoleau EORTC New Drug Development Group 2004 RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group Eur J Cancer 40 1332 1334
22. D Papahadjopoulos TM Allen A Gabizon 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci U S A 88 11460 11464
23. H Maeda J Wu T Sawa Y Matsumura K Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 271 284
24. Zamboni WC, Strychor S, Joseph E, Walsh DR, Parise RA, Tonda ME, Yu NY, Engber C, Eiseman JE (2005) Plasma and tumor disposition of STEALTH Liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenograft. Proc Am Acad Clin Res-NCI-EORTC: #B173
25. WC Zamboni JE Eiseman S Strychor PM Rice E Joseph DM Potter J Shurer DR Walsh RA Parise ME Tonda NY Yu C Engber PH Basse 2006 Relationship between the plasma and tumor disposition of STEALTH liposomal CKD-602 and macrophages/dendritic cells (MDC) in mice bearing human tumor xenografts Proc Am Acad Clin Res 47 1280
26. S Strychor JE Eiseman E Joseph RA Parise ME Tonda NY Yu C Engber WC Zamboni 2006 Plasma, tissue, and tumor disposition of STEALTH liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts Proc Am Acad Clin Res 47 721
27. WC Zamboni DM Friedland S Ramalingam RP Edwards RG Stoller CP Belani S Strychor YC Ou ME Tonda RK Ramanathan 2006 Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors Proc Am Soc Clin Oncol 24 82s
28. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington DC